Skip to content

The Combination of Propofol and Alfentanil for Painless Oocyte Retrieval: A Study Using Response Surface Methodology

The Combination of Propofol and Alfentanil for Painless Oocyte Retrieval: A Study Using Response Surface Methodology

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400083913
Enrollment
Unknown
Registered
2024-05-07
Start date
2024-05-20
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless Ovulation retrieval

Interventions

test group 1:Targeted control infusion of 0 ng/ml alfentanil
test group 2:Targeted control infusion of 15ng/ml alfentanil
test group 3:Targeted control infusion of 30 ng/ml alfentanil
test group 4:Targeted control infusion of 45 ng/ml alfentanil
test group 5:Targeted control infusion of 60 ng/ml alfentanil
test group 6:Targeted control infusion of 75 ng/ml alfentanil
test group 7:Targeted control infusion of 90 ng/ml alfentanil
test group 8:Targeted control infusion of 105 ng/ml alfentanil

Sponsors

Shanxi Bethune Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 50 Years

Inclusion criteria

Inclusion criteria: ?Those who intend to undergo painless egg retrieval in our hospital on an elective basis; ? 18.5 kg/? = BMI <28 kg/? ; ? American Society of Anesthesiologists of New York (ASA) grade ? ~ ?, without contraindications to general anesthesia.

Exclusion criteria

Exclusion criteria: ? Those who refuse to sign the informed consent form or are otherwise considered unsuitable for the clinical trial by the investigator; ? Those who have participated in clinical trials of other drugs in the last 4 weeks; ? Those with allergic constitution and allergic asthma; ? Those with a history of alcohol abuse and psychiatric system diseases, or a history of long-term use of psychotropic drugs, or cognitive dysfunction; ? Those with respiratory sleep apnea syndrome or anticipated difficult airway; (vi) Those with a recent history of acute infection; (vii) Those with hearing impairment.

Design outcomes

Primary

MeasureTime frame
Plasma concentrations of afentanil and propofol in each patient at the time of sedation and analgesia;

Secondary

MeasureTime frame
Hemodynamic stability;Effects on respiration;Follicle quality;nausea and vomiting;Total consumption of propofol ;Total consumption of alfentanil;Surgery time;awakening time;Immediate post awakening pain score;

Countries

China

Contacts

Public ContactPing Zhuang

Shanxi Bethune Hospital

13700503507@163.com+86 137 0050 3570

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026